A New Brain-Sparing Anti-Obesity Drug to Avoid Adverse Cardiovascular Effects

This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication. Anti-obesity drugs in the amphetamine (AMPH) class act on the brain to reduce appetite and increase locomotion but produce adverse cardiovascular effects. These can be circumvented by PEGylation (PEGyAMPH). PEGyAMPH does not enter the brain and protects mice against obesity, increasing lipolysis and thermogenesis, coupled to heat dissipation, becoming a novel class of exclusively peripheral anti-obesity sympathofacilitators that are devoid of any cardiovascular and brain-related side effects.

Yes, you can customize this template with a free BioRender account (no credit card required). Paid plans unlock additional export formats, higher-resolution downloads, and publication permissions.

Yes, every element is fully editable. Icons, labels, colors, arrows, shapes and layout can all be changed to match your preferences or needs using BioRender's drag-and-drop editor. You can add or remove elements to fully customize your use case.

Yes, BioRender icons and templates meet journal, grant, and copyright standards for publication, and many researchers cite BioRender directly in their figure legends.

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Researchers and scientists use this template for publications, funding proposals, grant applications, presentations, posters, and more.